Healthcare professionals often rely on clinical trials to help us understand the efficacy and safety of new medications. However, recent reports of unlisted side effects in patients using new diet drugs have raised concerns and questions within the medical community. Understanding the reasons behind these discrepancies is crucial for providing the best care to patients.

Starting today, a new rule requires drug commercials to clearly show the potential side effects and when not to take the medicine. This update to a 2007 law gives the FDA more control over drug advertising. Drugmakers have six months to comply with the new rule fully, and it’s unclear how aggressively the FDA will enforce the requirements, per Ropes & Gray. It’s a good step, but a lot more is needed.

Prescription drug advertising has increased year after year, but are THE ads really effective? The FDA is requiring a statutory requirement that in human prescription drug advertisements presented directly to consumers in television or radio format and stating the name of the drug and its conditions of use (DTC TV/radio ads), the major statement relating to side effects and contraindications must be presented in a clear, conspicuous, and neutral manner.

ALS is a fatal neurodegenerative condition that affects chewing, talking, and walking, progresses to paralysis, and culminates in respiratory failure, typically within three to five years. An estimated 30,000 Americans live with ALS, sometimes called Lou Gehrig’s disease. On Sept. 29, the Food and Drug Administration approved Relyvrio from Amylyx Pharmaceuticals. It’s the first ALS medication to be approved in five years and only one of three currently prescribed to patients to slow the progression of the disease, but should it have been approved?